ARVO Annual Meeting
May 3-7, 2026
Denver, USA
https://www.arvo.org/annual-meeting
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Downloads
Upcoming
Events
BIO International Convention
June 22-25, 2026
San Diego, USA
https://convention.bio.org/
CRS (Controlled Release Society) Annual Meeting
July 6-9, 2026
Lisbon, Portugal
https://www.controlledreleasesociety.org/events/crs-2026-annual-meeting-exposition
CPHI South East Asia
July 8-10, 2026
Bangkok, Thailand
https://www.cphi.com/sea/en/attend/attend/why-attend.html
CPHI Milan
October 6-8, 2026
Milan, Italy
https://www.cphi.com/europe/en/exhibit/book-your-stand-milan.html
PODD – Partnership Opportunities in Drug Delivery
October 29-30, 2026
Boston, USA
https://poddconference.com/
BIO-Europe
November 9-11, 2026
Cologne, Germany
https://informaconnect.com/bioeurope/
Past
Events
Archive
AT Uro Congress
May 22-24, 2025
Vienna, Austria
International Partnering in Life-Sciences Society (IPLS)
September 29 – October 1, 2025
Berlin, Germany
https://ipls.online/events/
CPHI Frankfurt
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
PharmaSynergyRx
February 5-6, 2026
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2026/
EuroPLX
March 2-3, 2026
Lisbon, Portugal
https://www.raucon.com/euro-plx/euro-p-l-x-90
BIO-Europe Spring
March 23-25, 2026
Lisbon, Portugal
https://informaconnect.com/bioeurope-spring/
DCAT Week
March 23-26, 2026
New York City, USA
https://dcatweek.org/
PBP World Meeting
March 23-26, 2026
Prague, Czech Republic
https://worldmeeting.org/
analytica
March 24-27, 2026
Munich, Germany
https://analytica.de/de/muenchen/
Latest
News
AMW reports financial results for fiscal 2022 and updates on corporate performance
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today released its financial results for the year ended December 31, 2022. AMW reported record consolidated sales for 2022 of €22.8 million and achieved operating profitability for the first time in the company’s history. The company also reported that Philipp Karbach will assume the position of chief executive officer (CEO) effective June 1, 2023, as Dr. Konstantin Petropoulos has decided to step down as CEO of AMW GmbH effective May 31, 2023, to pursue new opportunities. Philipp Karbach joined AMW in 2016, most recently in his role as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
read moreAMW Appoints Professor Olivia Merkel to the Scientific Advisory Board
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor of Drug Delivery at the Faculty of Chemistry and Pharmacy of Ludwig-Maximilians-Universität (LMU) Munich, as a member of its Scientific Advisory Board (SAB). Prof. Merkel is an internationally recognized expert in novel and targeted drug delivery systems, including RNA delivery systems. Her appointment will strengthen AMW’s scientific expertise in sustained-release delivery systems, such as biodegradable implants, and contribute to the company’s strategic development plans. With her appointment, Prof. Merkel succeeds Prof. Dr. Gerhard Winter, who will step down from his position on the Scientific Advisory Board.
read moreAMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a presence in the MENA (North Africa and Middle East) states, announced today that they have entered into an exclusive licensing and supply agreement. The agreement covers the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.
read moreFurther EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that the leuprorelin implant it developed has received additional marketing approvals in two European Union countries. Leuprorelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate cancer, and of certain gynecological diseases. AMW’s leuprorelin implant is now approved as a cost-effective therapy in over ten countries worldwide.
read moreAMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.
read more